FIELD: medicine.
SUBSTANCE: invention relates to a method for assessment of a suitable therapeutic dose of Siponimod. A method for the treatment of a patient suffering from an autoimmune condition is disclosed, including following stages: determination, whether the patient has a slow metabolizer genotype selected from CYP2C9*3*3 and CYP2C9*2*3 genotypes; and, if the patient is defined as not having the slow metabolizer genotype, administration of Siponimod or its pharmaceutically acceptable salt to the patient at a standard therapeutic dose; or, if the patient is defined as having the slow metabolizer genotype, administration of Siponimod or its pharmaceutically acceptable salt to the patient at a therapeutic dose, which is lower than the standard therapeutic dose.
EFFECT: invention provides administration to a patient of a suitable therapeutic dose of Siponimod.
12 cl, 8 dwg, 5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR MODULATORS AND USING THEM FOR TREATING MUSCULAR TISSUE INFLAMMATION | 2009 |
|
RU2521286C2 |
| 1-[4-[1-(4-CYCLOHEXYL-3-TRIFLUOROMETHYLBENZYLOXYIMINO)ETHYL]-2-ETHYL BENZYL]AZETIDINE-3-CARBOXYLIC ACID HEMIFUMARATE SALT | 2009 |
|
RU2518114C2 |
| COMBINED VORICONASOL AND ANTIMYCOTIC INHIBITOR CYP2C19 | 2005 |
|
RU2345769C2 |
| IMMUNOSUPPRESSIVE COMPOUNDS AND COMPOSITIONS | 2004 |
|
RU2405768C2 |
| COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHIES | 2009 |
|
RU2523281C2 |
| METHODS FOR TREATMENT OF GAUCHER DISEASE | 2018 |
|
RU2781242C2 |
| GENOTYPE- OR PHENOTYPE-BASED DRUG FORMULATION | 2013 |
|
RU2683260C2 |
| COMPOSITION FOR INHIBITING SYNTHESIS OF 5-HT2B AGONIST AND METHODS OF USE THEREOF | 2017 |
|
RU2746000C2 |
| PAROXETINE DERIVATIVE | 2013 |
|
RU2616610C2 |
| DERIVATIVES OF SITAXENTHAN | 2013 |
|
RU2622386C2 |
